This is a preview of subscription content, log in via an institution to check access.
Notes
Three of the authors of the study were affiliated with Novartis Pharmaceutical Corporation, US.
Reference
Tremblay G, et al. Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States. ClinicoEconomics and Outcomes Research : 12 Nov 2019. Available from: URL: https://doi.org/10.2147/CEOR.S226323
Rights and permissions
About this article
Cite this article
Eltrombopag in aplastic anaemia: higher response rates, higher cost. PharmacoEcon Outcomes News 842, 10 (2019). https://doi.org/10.1007/s40274-019-6402-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6402-8